Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$167.67
pos +1.11
+0.67%
Today's Range: 165.77 - 168.05 | AMGN Avg Daily Volume: 2,807,100
Last Update: 07/26/16 - 4:00 PM EDT
Volume: 2,869,156
YTD Performance: 2.61%
Open: $165.89
Previous Close: $166.56
52 Week Range: $130.09 - $181.81
Oustanding Shares: 751,217,078
Market Cap: 124,454,133,312
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 10 9 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.34 2.30 2.30 2.30
Latest Dividend: 1.00
Latest Dividend Yield: 2.41%
Dividend Ex-Date: 08/15/16
Price Earnings Ratio: 15.38
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
15.38 17.50 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.90% 5.03% 52.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $2.74 $2.78 $11.18 $12.04
Number of Analysts 11 9 12 12
High Estimate $2.94 $3.22 $12.23 $13.61
Low Estimate $2.60 $2.64 $10.92 $11.20
Prior Year $2.57 $2.72 $10.38 $11.18
Growth Rate (Year over Year) 6.54% 2.12% 7.71% 7.66%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jul 25, 2016 | 11:52 AM EDT
The market continues to trade lower as we late morning, with Tobira Therapeutics (TBRA) serving as the "disaster du jour" in the small-cap biotech space.
By

Bret Jensen

 | Jul 12, 2016 | 11:00 AM EDT
A look at who will be up and who will down this earnings season.
By

Bret Jensen

 | Jul 8, 2016 | 1:00 PM EDT
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
By

Bruce Kamich

 | Jul 5, 2016 | 2:42 PM EDT

Traders and investors should either stand aside or start probing the short side.

By

Bret Jensen

 | Jun 20, 2016 | 12:00 PM EDT

Large biotech stocks are still at their cheapest valuations since 2011.

By

Gary Morrow

 | May 25, 2016 | 3:22 PM EDT

A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term. 

By

Bret Jensen

 | May 24, 2016 | 11:00 AM EDT

Keep cash on hand and be ready for oportunities as they arise.

By

Skip Raschke

 | May 24, 2016 | 8:30 AM EDT

I prefer a bullish synthetic call.

By

Carolyn Boroden

 | May 23, 2016 | 8:00 AM EDT

But there is no guarantee that it will fully play out.

By

Bret Jensen

 | May 17, 2016 | 10:00 AM EDT

It is hard to see much growth in the market overall, until earnings growth returns.

The stock and bond markets have been as close to being "closed" as they can get while the ...
Since its recovery-rally high at 101 last Thursday, Apple Inc. (AAPL) has given back about...
First off, GILD was an unmitigated disaster, we cut this and ran. this is ugly here,...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.